|Day Low/High||76.40 / 77.35|
|52 Wk Low/High||65.25 / 92.64|
It's simply a little consolidation after a huge run. But could it develop?
What a strange day -- maybe even ominous. This table tells it all. The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...
It may be time to embrace the contrary. First issue (!!): The Palm Beach Chronicles. My weekly (brief) technical review of the markets -- cooling off ahead? BTIG's Stockton is bullish and so, as I have expressed, are most others! Campbell ...
"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly "The Good, the Bad and the Ugly" I did only a small amount of trading today (and added to short exposure), and there will be no "Takeaways" today (it's family ti...
Wall Street ran at two speeds with the Dow Jones Industrial Average setting a record high earlier in the day while the Nasdaq plummeted into the red.
But don't buy blindly. There are too many companies that can be retaliated against.
"Dougie, take what Mr. Market gives you." -- Grandma Koufax And I did, Grandma Koufax. A consecutive nine-day market drop was snapped as we regained most that was lost in that period. Today was a great day. (Boy, would I like to annualize the pe...
After the election passes we are going to talk about companies again -- and these have done well.
Avoid stocks with poor numbers that would suffer under a Clinton administration.
Stocks in the health care sector seem to have no underpinnings whatsoever.
In a "take no pain, take no prisoners" market, health care stocks languish.
Posting results 'not as a bad as we thought' has become a successful strategy. It worked for Bristol.
The pharmaceutical giant has reason to be optimistic about its earnings release tomorrow.
Thus far I am seeing a mixed picture of earnings reports this morning and last night. Visa guided a bit lower on a more costly Visa Europe integration, Whirlpool misses and cuts guidance, and Lilly results were well below on both earnings per share ...
On Tuesday, October 25, Apple reports fiscal fourth quarter results after the markets close.
Since mid- July there have been numerous negative divergences. One clear example is the chart below of new highs. During this three-and-a-half month period the S&P 500 has traded in a range above 2125 (the post-Brexit breakout). Downside attempts li...
The stock's healthy recent pattern appears to be giving way to a fresh bull leg.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
U.S. stocks rose Monday as Wall Street looked past Sunday night's bitter presidential debate, focusing instead on oil's 3% rally and the looming start of earnings season.
Zoetis is not averse to a little noise as investors, analysts take notice.
Merck has decided to discontinue the development of its osteoporosis drug and will not seek regulatory approval for its use.
The tactic is a slightly out-of-the-money, bearishly biased vertical put spread expiring in November.
The market continues to defy those players who believe we are seeing the calm before the storm.